» Articles » PMID: 22145865

Genomic Profiling of Renal Cell Carcinoma in Patients with End-stage Renal Disease

Abstract

The purpose of the present study was to determine the genomic profile of renal cell carcinoma (RCC) in end-stage renal disease (ESRD) by analyzing genomic copy number aberrations. Seventy-nine tumor samples from 63 patients with RCC-ESRD were analyzed by array comparative genomic hybridization using the Agilent Whole Human Genome 4 × 44K Oligo Micro Array (Agilent Technologies Inc., Palo Alto, CA, USA). Unsupervised hierarchical clustering analysis revealed that the 63 cases could be divided into two groups, Clusters A and B. Cluster A was comprised mainly of clear cell RCC (CCRCC), whereas Cluster B was comprised mainly of papillary RCC (PRCC), acquired cystic disease (ACD)-associated RCC, and clear cell papillary RCC. Analysis of the averaged frequencies revealed that the genomic profiles of Clusters A and B resembled those of sporadic CCRCC and sporadic PRCC, respectively. Although it has been proposed on the basis of histopathology that ACD-associated RCC, clear cell papillary RCC and PRCC-ESRD are distinct subtypes, the present data reveal that the genomic profiles of these types, categorized as Cluster B, resemble one another. Furthermore, the genomic profiles of PRCC, ACD-associated RCC and clear cell papillary RCC admixed in one tissue tended to resemble one another. On the basis of genomic profiling of RCC-ESRD, we conclude that the molecular pathogenesis of CCRCC-ESRD resembles that of sporadic CCRCC. Although various histologic subtypes of non-clear cell RCC-ESRD have been proposed, their genomic profiles resemble those of sporadic PRCC, suggesting that the molecular pathogenesis of non-CCRCC-ESRD may be related to that of sporadic PRCC.

Citing Articles

Is End-Stage Renal Disease Tumor Suppressive? Dispelling the Myths.

Migita T Cancers (Basel). 2024; 16(18).

PMID: 39335107 PMC: 11430482. DOI: 10.3390/cancers16183135.


Increased level of TXNIP and nuclear translocation of TXN is associated with end stage renal disease and development of multiplex renal tumours.

Beothe T, Docs J, Kovacs G, Peterfi L BMC Nephrol. 2024; 25(1):227.

PMID: 39020292 PMC: 11256699. DOI: 10.1186/s12882-024-03653-4.


Renal Cell Carcinoma in End-Stage Renal Disease: A Retrospective Study in Patients from Hungary.

Semjen D, Denes B, Somoracz A, Fintha A, Forika G, Jenei A Pathobiology. 2023; 90(5):322-332.

PMID: 36696889 PMC: 10614572. DOI: 10.1159/000529276.


Renal Cell Carcinoma in End-Stage Renal Disease: A Review and Update.

El-Zaatari Z, Truong L Biomedicines. 2022; 10(3).

PMID: 35327459 PMC: 8944945. DOI: 10.3390/biomedicines10030657.


Clear Cell Papillary Renal Cell Carcinoma Shares Distinct Molecular Characteristics and may be Significantly Associated With Higher Risk of Developing Second Primary Malignancy.

Tian X, Xu W, Wu J, Gan H, Wang H, Gu W Pathol Oncol Res. 2021; 27:1609809.

PMID: 34512202 PMC: 8432294. DOI: 10.3389/pore.2021.1609809.


References
1.
Kuroda N, Shiotsu T, Hes O, Michal M, Shuin T, Lee G . Acquired cystic disease-associated renal cell carcinoma with gain of chromosomes 3, 7, and 16, gain of chromosome X, and loss of chromosome Y. Med Mol Morphol. 2011; 43(4):231-4. DOI: 10.1007/s00795-009-0465-8. View

2.
Ianhez L, Lucon M, Nahas W, Sabbaga E, Saldanha L, Lucon A . Renal cell carcinoma in renal transplant patients. Urology. 2007; 69(3):462-4. DOI: 10.1016/j.urology.2006.11.007. View

3.
Sule N, Yakupoglu U, Shen S, Krishnan B, Yang G, Lerner S . Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study. Am J Surg Pathol. 2005; 29(4):443-51. DOI: 10.1097/01.pas.0000152131.58492.97. View

4.
Choyke P . Acquired cystic kidney disease. Eur Radiol. 2000; 10(11):1716-21. DOI: 10.1007/s003300000601. View

5.
Gobbo S, Eble J, Grignon D, Martignoni G, MacLennan G, Shah R . Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol. 2008; 32(8):1239-45. DOI: 10.1097/PAS.0b013e318164bcbb. View